Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Closes on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics announced today that it has closed its public offering of more than 6.3 million shares of its common stock at $12.50 per share.

The total number of shares sold includes 825,000 shares purchased by the offering's underwriters at $12.50 per share to cover over-allotments. The Mountain View, Calif., company had previously said that with the exercise of the over-allotment option, the net proceeds from the offering would be about $73.8 million.

Jefferies and UBS Investment Bank were joint book-running managers, while Baird and Cowen served as co-managers for the offering.

In a filing with the US Securities and Exchange Commission last month, Complete Genomics said that about $20 million of the net proceeds will be used to expand its sequencing and computing capacity in its facilities in Mountain View and Santa Clara, Calif. About $15 million will go toward further development of its sequencing technology and services, and $15 million will be used for sales and marketing activities.

The remainder of the net proceeds will go toward working capital and general corporate purposes.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.